학술논문
1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S680-S680
Subject
Language
ISSN
0923-7534